Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.48 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196656 | 1.00 | PTGS1 (0.48) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL18725045 | 0.93 | MEN1 (0.47) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL6546117 | 0.93 | PTGS1 (0.44) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL8755089 | 0.93 | CYP1A2 (0.50) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL8382637 | 0.89 | ALOX5AP (0.51) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL1131597 | 0.88 | PTGS1 (0.56) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL18211412 | 0.87 | NPC1 (0.42) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL12893262 | 0.87 | PTGS1 (0.40) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL18133126 | 0.87 | HPGD (0.50) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL13719538 | 0.87 | TEAD4 (0.48) | PTGS1PTGS2LMNACYP2C9AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | GILEAD PHARMASSET LLC | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | ENTPD5, DUT, NT5C3B | PTGS1 4490/4885PTGS2 4225/4885LMNA 2744/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | PTGS1 4508/4885PTGS2 4235/4885LMNA 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.